The Challenge of Indefinite Therapy in Chronic Lymphocytic Leukemia
The landscape of Chronic Lymphocytic Leukemia (CLL) treatment has been fundamentally altered by the advent of Bruton tyrosine kinase (BTK) inhibitors. Ibrutinib, the first-in-class BTK inhibitor, shifted the paradigm from intensive chemoimmunotherapy to targeted oral treatment. While ibrutinib significantly improves progression-free and overall survival, it rarely achieves complete response (CR) or undetectable measurable residual disease (uMRD). Consequently, patients typically remain on ibrutinib indefinitely, leading to concerns regarding long-term toxicity, financial burden, and the eventual development of resistance mutations in BTK or PLCG2. The clinical community has therefore sought ‘finite’ therapy options that can induce deep, durable remissions allowing for treatment discontinuation.
One promising strategy involves targeting the B-cell-activating factor receptor (BAFF-R), which is essential for the survival and maturation of B cells. Ianalumab (VAY736) is a novel, humanized, Fc-engineered monoclonal antibody that targets BAFF-R. It exerts its antitumor effect through two primary mechanisms: direct blockade of BAFF-R signaling and enhanced antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Preclinical models suggested that the combination of ianalumab and ibrutinib could synergistically reduce tumor burden and overcome the limitations of BTK inhibition alone.
